{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:18:56Z","timestamp":1782872336472,"version":"3.54.5"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2001,5,2]]},"abstract":"<jats:p>Clinical breast and pelvic examinations are commonly accepted practices prior to provision of hormonal contraception. Such examinations, however, may reduce access to highly effective contraceptive methods, and may therefore increase women's overall health risks. These unnecessary requirements also involve ethical considerations and unwittingly reinforce the widely held but incorrect perception that hormonal contraceptive methods are dangerous.<\/jats:p><jats:p>This article reviews and summarizes the relevant medical literature and policy statements from major organizations active in the field of contraception. Consensus developed during the last decade supports a change in practice: hormonal contraception can safely be provided based on careful review of medical history and blood pressure measurement. For most women, no further evaluation is necessary. Pelvic and breast examinations and screening for cervical neoplasia and sexually transmitted infection, while important in their own right, do not provide information necessary for identifying women who should avoid hormonal contraceptives or who need further evaluation before making a decision about their use.<\/jats:p>","DOI":"10.1001\/jama.285.17.2232","type":"journal-article","created":{"date-parts":[[2003,3,18]],"date-time":"2003-03-18T15:05:58Z","timestamp":1047999958000},"page":"2232","source":"Crossref","is-referenced-by-count":135,"title":["Clinical Breast and Pelvic Examination Requirements for Hormonal Contraception"],"prefix":"10.1001","volume":"285","author":[{"given":"Felicia H.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia C.","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Ellertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Grimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George F.","family":"Sawaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Trussell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"ref-jsc00381-4","article-title":"Labeling guidance text for combination oral contraceptives, prescribing information, physician labeling.","author":"Food and Drug Administration","year":"1994"},{"key":"ref-jsc00381-6","first-page":"27","article-title":"First prescription of combined oral contraception: recommendations for clinical practice.","volume":"26","author":"Faculty of Family Planning and Reproductive Health Care, Royal College of Obstetricians and Gynaecologists","year":"2000","journal-title":"Br J Fam Plann"},{"key":"ref-jsc00381-7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0010-7824(96)00167-9","article-title":"Evidence-guided prescribing of combined oral contraceptives: consensus statement, March 1996.","volume":"54","author":"Hannaford","year":"1996","journal-title":"Contraception"},{"key":"ref-jsc00381-8","first-page":"1","article-title":"IMAP statement on steroidal oral contraception.","volume":"29","author":"International Planned Parenthood Federation","year":"1995","journal-title":"IPPF Med Bull"},{"key":"ref-jsc00381-9","first-page":"1","article-title":"IMAP statement on injectable contraception.","volume":"33","author":"International Planned Parenthood Federation","year":"1999","journal-title":"IPPF Med Bull"},{"key":"ref-jsc00381-12","first-page":"4","article-title":"Revised oral contraceptive labeling: FDA approves recommendation allowing delay of pelvic exam.","volume":"4","author":"Not Available","year":"1993","journal-title":"Contracept Rep"},{"key":"ref-jsc00381-18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/1054-139X(94)90262-3","article-title":"SMART START: an option for adolescents to delay the pelvic examination and blood work in family planning clinics.","volume":"15","author":"Armstrong","year":"1994","journal-title":"J Adolesc Health"},{"key":"ref-jsc00381-19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2307\/2673737","article-title":"Provision of hormonal contraceptives without a mandatory pelvic exam: the First Stop demonstration project.","volume":"33","author":"Harper","year":"2001","journal-title":"Fam Plann Perspect"},{"key":"ref-jsc00381-20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0010-7824(01)00175-5","article-title":"Cervical neoplasia risk in women provided hormonal contraception without a Pap smear.","volume":"63","author":"Sawaya","year":"2001","journal-title":"Contraception"},{"key":"ref-jsc00381-21","doi-asserted-by":"crossref","DOI":"10.2307\/2991523","article-title":"Does the timing of the first family planning visit still matter?","volume":"30","author":"Finer","year":"1998","journal-title":"Fam Plann Perspect"},{"key":"ref-jsc00381-22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1001\/jama.1996.03530260027026","article-title":"Adolescents with negative pregnancy test results: an accessible at-risk group.","volume":"275","author":"Zabin","year":"1996","journal-title":"JAMA"},{"key":"ref-jsc00381-23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3109\/00016349509008923","article-title":"Experiences of the first pelvic examination in a random samples of Danish teenagers.","volume":"74","author":"Larsen","year":"1995","journal-title":"Acta Obstet Gynecol Scand"},{"key":"ref-jsc00381-24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0197-0070(84)80008-X","article-title":"Sources of anxiety about pelvic examinations among adolescent females.","volume":"5","author":"Millstein","year":"1984","journal-title":"J Adolesc Health Care"},{"key":"ref-jsc00381-25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1300\/J013v21n01_03","article-title":"Increasing the incidence of routine pelvic examinations: behavioral medicine's contribution.","volume":"21","author":"Frye","year":"1994","journal-title":"Women Health"},{"key":"ref-jsc00381-26","doi-asserted-by":"publisher","first-page":"29S","DOI":"10.1016\/S0010-7824(98)00135-8","article-title":"Oral contraceptive health benefits: perception versus reality.","volume":"59","author":"Kaunitz","year":"1999","journal-title":"Contraception"},{"key":"ref-jsc00381-27","first-page":"1","article-title":"IMAP statement on steroidal oral contraception.","volume":"29","author":"International Planned Parenthood Federation","year":"1995","journal-title":"IPPF Med Bull"},{"key":"ref-jsc00381-29","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1001\/jama.282.13.1270","article-title":"Does this patient have breast cancer?","volume":"282","author":"Barton","year":"1999","journal-title":"JAMA"},{"key":"ref-jsc00381-31","first-page":"1","article-title":"Fertility, family planning, and women's health: new data from the 1995 National Survey of Family Growth.","volume":"19","author":"Abma","year":"1997","journal-title":"Vital Health Stat. Series 23: Data from the National Survey of Family Growth"},{"key":"ref-jsc00381-33","doi-asserted-by":"crossref","DOI":"10.2307\/2953412","article-title":"Medical care cost savings from adolescent contraceptive use.","volume":"29","author":"Trussell","year":"1997","journal-title":"Fam Plann Perspect"},{"key":"ref-jsc00381-34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0010-7824(97)00201-1","article-title":"Oral contraceptive use and benign gynecologic conditions: a review.","volume":"57","author":"Chiaffarino","year":"1998","journal-title":"Contraception"},{"key":"ref-jsc00381-35","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/bjo.1999.106.issue-8","article-title":"Use of oral contraceptives and uterine fibroids:  results from a case-control study.","volume":"106","author":"Chiaffarino","year":"1999","journal-title":"Br J Obstet Gynaecol"},{"key":"ref-jsc00381-36","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0002-9378(99)70664-2","article-title":"Condom practices of urban teens using Norplant contraceptive implants, oral contraceptives, and condoms for contraception.","volume":"180","author":"Darney","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"ref-jsc00381-37","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ije\/19.1.4","article-title":"Oral contraceptive use and risk of invasive cervical cancer.","volume":"19","author":"Brinton","year":"1990","journal-title":"Int J Epidemiol"},{"key":"ref-jsc00381-38","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/0010-7824(91)90005-Z","article-title":"Oral contraceptives and cervical neoplasia.","volume":"43","author":"Brinton","year":"1991","journal-title":"Contraception"},{"key":"ref-jsc00381-39","first-page":"3657","article-title":"Risk factors for in situ cervical cancer: results from a case-control study.","volume":"50","author":"Jones","year":"1990","journal-title":"Cancer Res"},{"key":"ref-jsc00381-40","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/BF00052426","article-title":"Case-control study of risk factors for cervical squamous-cell neoplasia in Denmark: role of oral contraceptive use.","volume":"4","author":"Kjaer","year":"1993","journal-title":"Cancer Causes Control"},{"key":"ref-jsc00381-41","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/(ISSN)1097-0215","article-title":"Association of oral contraceptive use and human papillomaviruses in invasive cervical cancers.","volume":"45","author":"Hildesheim","year":"1990","journal-title":"Int J Cancer"},{"key":"ref-jsc00381-42","first-page":"4670","article-title":"Oral contraceptive use, human papillomavirus infection, and risk of early cytological abnormalities of the cervix.","volume":"50","author":"Negrini","year":"1990","journal-title":"Cancer Res"},{"key":"ref-jsc00381-43","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/S0140-6736(94)90567-3","article-title":"Oral contraceptive use and adenocarcinoma of cervix.","volume":"344","author":"Ursin","year":"1994","journal-title":"Lancet"},{"key":"ref-jsc00381-44","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S1054-139X(98)00066-4","article-title":"Annual pelvic examination in the sexually active adolescent female: what are we doing and why are we doing it?","volume":"23","author":"Shafer","year":"1998","journal-title":"J Adolesc Health"},{"key":"ref-jsc00381-45","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1056\/NEJM199612123352417","article-title":"Routine pelvic examinations in asymptomatic young women.","volume":"335","author":"Schachter","year":"1996","journal-title":"N Engl J Med"},{"key":"ref-jsc00381-48","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/00003081-199612000-00013","article-title":"The genetics of ovarian cancer: an assessment of current screening protocols and recommendations for counseling families at risk.","volume":"39","author":"Bombard","year":"1996","journal-title":"Clin Obstet Gynecol"},{"key":"ref-jsc00381-49","doi-asserted-by":"publisher","first-page":"408","DOI":"10.5694\/mja2.1995.162.issue-8","article-title":"Is there any value in bimanual pelvic examination as a screening test?","volume":"162","author":"Grover","year":"1995","journal-title":"Med J Aust"},{"key":"ref-jsc00381-50","first-page":"244","article-title":"Ovarian cancer screening: a primary care guide.","volume":"2","author":"Thompson","year":"1998","journal-title":"Lippincotts Primary Care Pract"},{"key":"ref-jsc00381-1","volume-title":"The Best Intentions: Unintended Pregnancy and the Well-Being of Children and Families","author":"Brown","year":"1995"},{"key":"ref-jsc00381-2","volume-title":"Guidelines for Women's Health Care","author":"American College of Obstetricians and Gynecologists","year":"1996"},{"key":"ref-jsc00381-3","volume-title":"Oral Contraceptives for Adolescents: Benefits and Safety","author":"American College of Obstetricians and Gynecologists","year":"1999"},{"key":"ref-jsc00381-10","first-page":"20","article-title":"The Canadian Consensus Conference on Contraception.","volume-title":"J SOGC","author":"Society of Obstetricians and Gynaecologists of Canada","year":"1998"},{"key":"ref-jsc00381-11","volume-title":"Physicians' Desk Reference","author":"Not Available","year":"1999","edition":"53rd ed."},{"key":"ref-jsc00381-13","volume-title":"Manual of Medical Standards and Guidelines","author":"New York: Planned Parenthood Federation of America","year":"1996"},{"key":"ref-jsc00381-14","volume-title":"Manual of Medical Standards and Guidelines: Hormonal Contraceptive Use","author":"New York: Planned Parenthood Federation of America","year":"1999"},{"key":"ref-jsc00381-15","volume-title":"Improving Access to Quality Care in Family Planning: Medical Eligibility Criteria For Initiating and Continuing Use of Contraceptive Methods","author":"World Health Organization","year":"1996"},{"key":"ref-jsc00381-16","volume-title":"Medical Eligibility Criteria For Initiating and Continuing Use of Contraceptive Methods","author":"World Health Organization","year":"2000"},{"key":"ref-jsc00381-17","volume-title":"Recommendations for Updating Selected Practices in Contraceptive Use, Volume I.","author":"World Health Organization and U.S. Agency for International Development","year":"1994"},{"key":"ref-jsc00381-28","volume-title":"SEER Cancer Statistics Review, 1973-1994","author":"Ries","year":"1997"},{"key":"ref-jsc00381-30","volume-title":"US Preventive Services Task Force, Guide to Clinical Preventive Services","author":"Not Available","year":"1996","edition":"2nd ed."},{"key":"ref-jsc00381-32","volume-title":"Contraceptive Technology","author":"Hatcher","year":"1998","edition":"17th ed."},{"key":"ref-jsc00381-46","volume-title":"Cancer incidence and mortality in California by race\/ethnicity, 1988-1993","author":"Perkins","year":"1996"},{"key":"ref-jsc00381-47","volume-title":"Technical Bulletin 198 on Hormonal Contraception","author":"American College of Obstetricians and Gynecologists","year":"1994"},{"key":"ref-jsc00381-5","unstructured":"Food and Drug Administration. Labeling guidance text for progestin-only oral contraceptives, prescribing information, physician labeling. Available at: http:\/\/www.fda.gov\/medwatch\/safety\/label\/guidance.htm; revised 1995. Accessibility verified April 11, 2001."}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/193803\/jsc00381_1665435947.70623.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T21:31:08Z","timestamp":1665437468000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/193803"}},"subtitle":["Current Practice vs Evidence"],"short-title":[],"issued":{"date-parts":[[2001,5,2]]},"references-count":50,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2001,5,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.285.17.2232","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2001,5,2]]}}}